Report of Foreign Issuer (6-k)
25 September 2020 - 1:01PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of September 2020
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
25 September 2020 07:00 BST
Non-Executive Board Appointment
AstraZeneca PLC today announced that with effect from 1 October
2020, Dr Euan Ashley is appointed as a Non-Executive Director and a
member of the Science Committee.
Leif Johansson, Chairman of AstraZeneca, said: "We look forward to
welcoming Euan to AstraZeneca and believe his scientific
achievements and interests, which are well-aligned with our own
BioPharmaceuticals R&D, together with his entrepreneurial
experience on the US west coast will enable him to make a
significant contribution to the Board's work."
Euan Ashley is Associate Dean and Professor of Cardiovascular
Medicine and Genetics at Stanford University in California.
Dr Ashley's research focuses on genetic mechanisms of
cardiovascular health and disease. In addition to wet bench
science, his laboratory leverages artificial intelligence and
digital health tools, working with biotechnology and technology
partners in Silicon Valley, to advance both translational and
clinical research.
Dr Ashley studied physiology and medicine at Glasgow University,
completing his junior doctor training at Oxford University
Hospitals NHS Trust, before undertaking a DPhil in cardiovascular
cellular biology and molecular genetics at the University of
Oxford. In 2002, he moved to Stanford University to train in
cardiology and advanced heart failure.
Dr Ashley has received many awards including recognition from the
Obama White House for contributions to personalized medicine and
the American Heart Association's Medal of Honor for precision
medicine.
No disclosure obligations arise under paragraphs (1) to (6) of LR
9.6.13 R of the UK Listing Authority's Listing Rules in respect of
this appointment.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three therapy
areas - Oncology, Cardiovascular, Renal & Metabolism, and
Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London
Stock Exchange. RNS is approved by the Financial Conduct Authority
to act as a Primary Information Provider in the United Kingdom.
Terms and conditions relating to the use and distribution of this
information may apply. For further information, please
contact rns@lseg.com or
visit www.rns.com.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
25 September
2020
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024